NEW YORK (GenomeWeb News) – Becton Dickinson today said fiscal third-quarter revenue increased 7 percent as R&D costs soared 42 percent and income grew 9 percent.
Receipts for the three months ended June 30 increased to $1.5 billion from $1.4 billion year over year.
The BD Biosciences segment reported the strongest growth, as revenues increased 9 percent to $219 million. Sales of flow cytometry instruments, reagents, and cell imaging products contributed to the rise.
R&D costs surged 42 percent $276 million from $195 million from the comparable quarter a year ago.
Net income for the third quarter increased to $206 million from $190 million during the comparable period last year.